143 related articles for article (PubMed ID: 35536548)
41. Novel therapeutic targets for inflammatory bowel disease.
Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
[TBL] [Abstract][Full Text] [Related]
42. Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases.
Clarke PA; Ortiz-Ruiz MJ; TePoele R; Adeniji-Popoola O; Box G; Court W; Czasch S; El Bawab S; Esdar C; Ewan K; Gowan S; De Haven Brandon A; Hewitt P; Hobbs SM; Kaufmann W; Mallinger A; Raynaud F; Roe T; Rohdich F; Schiemann K; Simon S; Schneider R; Valenti M; Weigt S; Blagg J; Blaukat A; Dale TC; Eccles SA; Hecht S; Urbahns K; Workman P; Wienke D
Elife; 2016 Dec; 5():. PubMed ID: 27935476
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.
McDermott MS; Chumanevich AA; Lim CU; Liang J; Chen M; Altilia S; Oliver D; Rae JM; Shtutman M; Kiaris H; Győrffy B; Roninson IB; Broude EV
Oncotarget; 2017 Feb; 8(8):12558-12575. PubMed ID: 28147342
[TBL] [Abstract][Full Text] [Related]
44. CDK8 kinase--An emerging target in targeted cancer therapy.
Rzymski T; Mikula M; Wiklik K; Brzózka K
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1617-29. PubMed ID: 26006748
[TBL] [Abstract][Full Text] [Related]
45. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
46. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
Rzymski T; Mikula M; Żyłkiewicz E; Dreas A; Wiklik K; Gołas A; Wójcik K; Masiejczyk M; Wróbel A; Dolata I; Kitlińska A; Statkiewicz M; Kuklinska U; Goryca K; Sapała Ł; Grochowska A; Cabaj A; Szajewska-Skuta M; Gabor-Worwa E; Kucwaj K; Białas A; Radzimierski A; Combik M; Woyciechowski J; Mikulski M; Windak R; Ostrowski J; Brzózka K
Oncotarget; 2017 May; 8(20):33779-33795. PubMed ID: 28422713
[TBL] [Abstract][Full Text] [Related]
47. Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.
Thirunavukkarasu K; Tan B; Swearingen CA; Rocha G; Bui HH; McCann DJ; Jones SB; Norman BH; Pfeifer LA; Saha JK
J Pharmacol Exp Ther; 2016 Oct; 359(1):207-14. PubMed ID: 27516465
[TBL] [Abstract][Full Text] [Related]
48. Allium sativum (garlic) suppresses leukocyte inflammatory cytokine production in vitro: potential therapeutic use in the treatment of inflammatory bowel disease.
Hodge G; Hodge S; Han P
Cytometry; 2002 Aug; 48(4):209-15. PubMed ID: 12210145
[TBL] [Abstract][Full Text] [Related]
49. A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery.
Cholko T; Chen W; Tang Z; Chang CA
J Comput Aided Mol Des; 2018 Jun; 32(6):671-685. PubMed ID: 29737445
[TBL] [Abstract][Full Text] [Related]
50. CDK8 Fine-Tunes IL-6 Transcriptional Activities by Limiting STAT3 Resident Time at the Gene Loci.
Martinez-Fabregas J; Wang L; Pohler E; Cozzani A; Wilmes S; Kazemian M; Mitra S; Moraga I
Cell Rep; 2020 Dec; 33(12):108545. PubMed ID: 33357429
[TBL] [Abstract][Full Text] [Related]
51. Retroviral cyclin enhances cyclin-dependent kinase-8 activity.
Rovnak J; Brewster CD; Quackenbush SL
J Virol; 2012 May; 86(10):5742-51. PubMed ID: 22379099
[TBL] [Abstract][Full Text] [Related]
52. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells.
He L; Lu N; Dai Q; Zhao Y; Zhao L; Wang H; Li Z; You Q; Guo Q
Toxicology; 2013 Oct; 312():36-47. PubMed ID: 23907061
[TBL] [Abstract][Full Text] [Related]
53. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
Perera AP; Kunde D; Eri R
Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
[TBL] [Abstract][Full Text] [Related]
54. A new target for the treatment of inflammatory bowel disease: Interleukin-37.
Jia Y; Anwaar S; Li L; Yin Z; Ye Z; Huang Z
Int Immunopharmacol; 2020 Jun; 83():106391. PubMed ID: 32208166
[TBL] [Abstract][Full Text] [Related]
55. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T
Akamatsu M; Mikami N; Ohkura N; Kawakami R; Kitagawa Y; Sugimoto A; Hirota K; Nakamura N; Ujihara S; Kurosaki T; Hamaguchi H; Harada H; Xia G; Morita Y; Aramori I; Narumiya S; Sakaguchi S
Sci Immunol; 2019 Oct; 4(40):. PubMed ID: 31653719
[TBL] [Abstract][Full Text] [Related]
56. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase.
Peifer C; Wagner G; Laufer S
Curr Top Med Chem; 2006; 6(2):113-49. PubMed ID: 16454763
[TBL] [Abstract][Full Text] [Related]
57. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease.
Sukocheva OA; Lukina E; McGowan E; Bishayee A
Adv Protein Chem Struct Biol; 2020; 120():123-158. PubMed ID: 32085881
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic implications of interleukin-10 in inflammatory bowel disease.
Shirachi A
Kurume Med J; 1998; 45(1):63-7. PubMed ID: 9658753
[TBL] [Abstract][Full Text] [Related]
59. Stability of Imprinting and Differentiation Capacity in Naïve Human Cells Induced by Chemical Inhibition of CDK8 and CDK19.
Bernad R; Lynch CJ; Urdinguio RG; Stephan-Otto Attolini C; Fraga MF; Serrano M
Cells; 2021 Apr; 10(4):. PubMed ID: 33921436
[TBL] [Abstract][Full Text] [Related]
60. Suppression of MAPKs/NF-κB Activation Induces Intestinal Anti-Inflammatory Action of Ginsenoside Rf in HT-29 and RAW264.7 Cells.
Ahn S; Siddiqi MH; Aceituno VC; Simu SY; Yang DC
Immunol Invest; 2016 Jul; 45(5):439-49. PubMed ID: 27224660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
